Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa

Launched by CENTRE HOSPITALIER RÉGIONAL D'ORLÉANS · Dec 13, 2024

Keywords

ClinConnect Summary

The ADDICT study is investigating the effectiveness of different antibiotic treatments for infections caused by a tough-to-treat bacteria called Pseudomonas aeruginosa. This bacteria can be challenging to treat because it often resists many common antibiotics. In this trial, researchers want to compare a newer type of antibiotic combination called cefiderocol with older antibiotics like aminoglycosides and colistin to see which works better for patients needing intravenous treatment.

To participate in this study, you need to be at least 18 years old and require intravenous antibiotic therapy for an infection caused by this difficult bacteria. However, people with cystic fibrosis or those who are not in need of immediate antibiotic treatment for their infection cannot join. If you decide to participate, you will receive one of the antibiotic treatments being studied, and researchers will monitor your progress to see how well the treatment is working. This trial aims to find better options for treating these complex infections, which could improve outcomes for many patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients aged 18 or over and requiring intravenous definite antimicrobial therapy for a DTR P. aeruginosa infection
• Exclusion Criteria:
• • Cystic fibrosis
• • P. aeruginosa DTR colonization or P. aeruginosa DTR infection not requiring definitive intravenous antibiotic therapy
• • Protected person (under guardianship or curatorship)
• • Persons under court protection
• • Persons deprived of liberty
• • Opposition expressed for participation in the study